New metabolic-endocrine risk markers in endometrial cancer

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 106, Issue 5, 1999, Pages 402-406

  Stoll, Basil A ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; ASCORBIC ACID; ESTROGEN; RETINOL; SOMATOMEDIN;

ANOVULATION; CANCER INCIDENCE; DIET; ENDOMETRIUM CANCER; FAMILY HISTORY; FEMALE; GENETICS; HUMAN; METABOLISM; OBESITY; PRIORITY JOURNAL; REVIEW; RISK; STEROIDOGENESIS;

DIET; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; RISK FACTORS; SOMATOMEDINS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032927381     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.1999.tb08290.x     Document Type: Review

References (84)

1. McPherson CP, Sellers TA, Potter JD, Bostick RM, Folsom AR. Reproductive factors and risk of endometrial cancer. Iowa Women's Health Study. Am J Epidemiol 1996; 143: 1195–1202.
2. Brinton LA, Berman ML, Mortel R et al. Reproductive, menstrual and medical risk factors for endometrial cancer: case-control study. Am J Obstet Gynecol 1992; 167: 1317–1325.
3. Austin H, Austin JM, Partridge EE, Hatch KD, Shingleton HM. Endometrial cancer, obesity and body fat distribution. Cancer Res 1991; 51: 568–572.
4. Nyholm HCJ, Nielsen AL, Lyndrup J, Dreisler A, Hagen C, Haug E. Plasma oestrogen in postmenopausal women with endometrial cancer. Br J Obstet Gynecol 1993; 100: 1115–1119.
5. Potischman N, Hoover RN, Brinton LA et al. Case control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 1996; 88: 1127–1135.
6. Persson I. Cancer risk in women receiving estrogen-progestin replacement therapy. Maturitas 1996; 23 (Suppl): 3745.
7. Pike MC, Peters RK, Comn W et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1097; 89; 1110–1116.
8. Key TJ, Pike MC. The dose-effect relationship between unopposed oestrogens and endometrial mitotic rate: its central role in endometrial cancer risk. Br J Cancer 1988; 57: 205–212.
9. Hulka BS. Epidemiologic analysis of breast and gynecologic cancers. Prog Clin Biol Res 1997; 396 17–29.
10. Key TJA, Pike MC, Brown JB, Hermon C, Allen DS. Wang DY. Cigarette smoking and urinary estrogen excretion in premenopausal and postmenopausal women. Br J Cancer 1996; 74; 1313–1316.
11. Folsom AR, Kaye SA, Potter JD, Prineas RJ. Association of incident carcinoma of the endometrium with body weight and fat distribution: Iowa Women's Health Study. Cancer Res 1989; 49; 6828–6831.
12. Le Marchand L, Wilkens LR, Mi MP. Early age body size, adult weight gain and endometrial cancer risk. Int J Cancer 1991; 48: 807–811.
13. Swanson CA, Potischman N, Wilbanks GD et al. Relation of endometrial cancer risk to past and contemporary body size and body fat distribution. Cancer Epidemiol Biomark Prev 1993; 2: 321–327.
14. Nagamani M, Stuart CA, Doherty MG. Increased steroid production by the ovarian stromal tissue of postmenopausal women with endometrial cancer. J Clin Endocrinol Metab 1992; 74: 172–176.
15. Bulun SE, Economos K. Miller D, Simpson ER. CYP19 (aromatase cytochrome p450) gene expression in malignant endometrial tumors. J Clin Endocrinol Metab 1994; 79: 1831–1834.
16. Parkin DM, Muir CS, Whelan SL. Cancer Incidence in Five Continents. Lyon: IARC Scientific Publications, no. 120, 1992.
17. Parazzini F, La Vecchia C, Moroni S, Chatenoud L, Ricci E. Family history and the risk of endometrial cancer. Int J Cancer 1994; 59: 46–62.
18. Peto J, Easton DF, Matthews FE, Ford D, Swerdlow AJ. Cancer mortality in relatives of women with breast cancer. Int J Cancer 1996; 59: 460–462.
19. Goodman MT, Hankin JH, Wilkens LR et al. Diet, body size, physical activity and the risk of endometrial cancer. Cancer Res 1997; 57: 5077–5085.
20. Schiff M, Key CR, Gilliland FD, Becker TM. Ethnic differences in uterine corpus cancer incidence and mortality in New Mexico's American Indians, Hispanics and non-Hispanic whites. Int J Epidemiol 1997; 26; 249–255.
21. Miller BA, Kolonel LM, Bernstein L. Racial/ethnic patterns of cancer in the United States 1988–1992; Bethesda MD: NCI/NIH (Publication 96–4104), 1006.
22. Inoue M, Okayama A, Fujita M, Onomoto T, Tanizawa O, Ueshima H. A case-control study on risk factors for uterine endometrial cancer in Japan. Jap J Cancer Res 1994; 85: 346–350.
23. Hirase K, Tajima K, Hamajima N et al. Specific risk and protective factors in uterine cancer. Jap J Cancer Res 1996; 87: 1001–1009.
24. Schottenfeld D. Epidemiology of endometrial neoplasia. J Cell Biochem 1995; 23 (Suppl): 151–159.
25. Dahlgren E, Friberg LG, Johansson S et al. Endometrial carcinoma: ovarian dysfunction is a risk factor in young women. Eur J Obstet Gynecol Reprod Biol 1991; 41: 143–150.
26. Kalandidi A, Tzonou A, Lipworth L, Gamatzi I, Filippa D, Trichopoulos D. A case-control study of endometrial cancer in relation to reproductive, somatometric and lifestyle variables. Oncology 1996; 53: 354–359.
27. De Waard F, De Ridder CM, Baanders van Halewyn EA, Slotboom BJ. Endometrial cancer in a cohort screened for breast cancer. Eur J Cancer Prev 1996; 5: 99–104.
28. Shu XO, Brinton LA, Zheng W et al. Relation of obesity and body fat distribution to endometrial cancer in Shanghai, China. Cancer Res 1992; 52: 3865–3870.
29. Lapidus L, Helgesson C, Merck C, Bjorntorp P. Adipose tissue distribution and female carcinoma: a 12 year study in Gothenberg, Sweden. Int J Obes 1988; 12: 361–368.
30. Elliott EA, Matanoski GM, Rosenshein NB. Body fat patterning in women with endometrial cancer. Gynecol Oncol 1990; 39 253–258.
31. Kirschner MA, Samolijk E, Drejka M, Szmal E, Schneider G, Ertel N. Androgen-estrogen metabolism in women with upper-body versus lower-body obesity. J Clin Endocrinol Metab 1990; 70 473–479.
32. Schapira DV, Kumar NB, Lyman GH, Cavanagh D, Roberts WS, La Polla J. Upper-body fat distribution and endometrial cancer risk. JAMA 1991; 266: 1808–1811.
33. Samaras K, Spector TD, Nguyen TV, Baan K, Campbell LV. Independent genetic factors determine the amount and distribution of fat in women after the menopause. J Clin Endocrinol Metab 1997; 82:.
34. Kissebah AH, Vydelingum N, Maurray R et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982; 54: 258–260.
35. Rutanen EM, Stenman S, Blum W, Karkkainen T, Lehtovirta P, Stenman UH. Relationship between carbohydrate metabolism and serum IGF system in postmenopausal women wtih endometrial cancer and controls. J Clin Endocrinol Metab 1993; 77: 199–204.
36. Brown R. Carbohydrate metabolism in patients with endometrial cancer. J Obstet Gynecol Br Comnwlth 1974; 81: 940–946.
37. Nagamani M, Hannigan EV, van Dinh T. Stuart CA. Hyperinsulinemia and stromal luteinization of the ovaries in postmenopausal women with endometrial cancer. J Clin Endocrinol Metab 1988; 67: 144–148.
38. Vishnevsky AS, Bobrov IF, Tsyrlina EV, Dilman VM. Hyperinsulinemia as a factor modifying sensitivity of endometrial carcinoma to hormonal influences. Eur J Gynaecol Oncol 1993; 14: 127–130.
39. Yam D, Ben Hur H, Fink A et al. Insulin and glucose status, tissue and plasma lipids in patients with tumours of the ovary or endometrium: possible dietary implications. Br J Cancer 1994; 70: 1186–1187.
40. Troisi R, Potischman N, Hoover RN, Siiteri P, Brinton LA. Insulin and endometrial cancer. Am J Epidemiol 1997; 146: 476–482.
41. Gamayunova VB, Bobrov YF, Tsyrlina EV, Evtushenko TP, Berstein LM. Comparative study of insulin levels in breast and endometrial cancer patients. Neoplasma 1997; 44: 123–126.
42. La Vecchia C, Negri E, Franceschi S, D'Avanzo B, Boyle P. A case-control study of diabetes and cancer risk. Br J Cancer 1994: 70: 950–953.
43. Vuento MH, Maatela JI, Tyrkko JE, Laippala PJ, Gronroos M, Salmi TA. Longitudinal study of screening for endometrial cancer by endometrial biopsy in diabetic females. Int J Gynecol Oncol 1995; 5: 390–395.
44. Hansen BC. Genetics of insulin action. Baillieres Clin Endocrinol Metab 1993; 7: 1033–1061.
45. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–1607.
46. Storlien LH, Baur LA, Kriketos AD, Pan DA, Cooney GJ. Dietary fats and insulin action. Diabetologia 1996; 39: 621–631.
47. Cook JS, Hoffman RP, Stere MA, Hansen JR. Effects of maturational age on insulin sensitivity during puberty. J Clin Endocrinol Metab 1993; 77: 725–730.
48. Giudice LC. Growth factors and growth modulators in human uterine endometrium: their potential relevance to reproductive medicine. Fertil Steril 1994; 61: 1–17.
49. Mogul HR, Marshall M, Frey M et al. IGFBP1 as a marker for hyperinsulinemia in obese menopausal women. J Clin Endocrinol Metab 1996; 81: 449–495.
50. Nagamani M, Stuart CA, Dunhardt PA, Doherty MG. Specific binding sites for insulin and IGFl in human endometrial cancer. Am J Obstet Gynecol 1991; 165: 1865–1871.
51. Rutanen EM, Nyman T, Lehtovirta P, Anmala M, Pekonen F. Suppressed expression of IGFBP1 mRNA in the endometrium: a molecular mechanism associating endometrial cancer with its risk factors. Int J Cancer 1994; 59: 307–312.
52. Frost RA, Mazella J, Tseng L. IGFBP1 inhibits the mitogenic effects of IGFs and progestins in human endometrial stromal cells. Biol Reprod 1993; 49 104–111.
53. Giudice LC, Dsupin BA, Irwin JC. Steroid and peptide regulation of IGFBPs secreted by human endometrial stromal cells is dependent on strod differentiation. J Clin Endocrinol Metab 1992; 75 1235–1241.
54. Ayabe T, Tsutsumi O, Sakai H et al. Increased circulating levels of IGF1 and decreased circulating levels of IGFBP1 in postmenopausal women with endometrial cancer. Endocrinol J 1997; 44: 419–424.
55. Kleinman D, Roberts Cr, Leroith D, Schally AV, Levy J, Sharoni Y. Regulation of endometrial cancer cell growth by IGFs and the LH-releasing hormone antagonist SB75. Regulatory Peptides 1993; 48:91–98.
56. Hana V, Murphy LJ. Expression of IGFs and their binding proteins in the estrogen-responsive Ishikawa human endometrial cancer cell line. Endocrinol 1994; 135: 2511–2516.
57. Kleinman D, Karas M, Danilenko M et al. Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased IGF-induced tyrosine phosphorylation and reduction in IGFBPs. Endocrinol 1996; 137: 1089–1095.
58. Giudice LC, Chandra-Sekher YA, Cataldo NA. The potential roles of intra-ovarian peptides in normal and abnormal mechanisms of reproductive physiology. Curr Opin Obstet Gynecol 1993; 5: 350–359.
59. Madigan MP, Troisi R, Potischman N, Dorgan JF, Brinton LA, Hoover RN. Serum hormone levels in relation to reproductive and lifestyle factors in postmenopausal women. Cancer Causes Control 1998; 9: 199–207.
60. Lee PDK, Giudice LC, Conover CA, Powell DR. IGFBP1: recent findings and new directions. Proc SOC Exp Bid Med 1997; 216; 319–357.
61. Adami HO, Bergstrom R, Weiderpass E, Persson I. Barlow L, McLaughlin JK. Risk for endometrial cancer following breast cancer: a prospective study in Sweden. Cancer Causes Control 1997; 8:.
62. Suomi R, Hakalaapietila T, Leminen A. Mecklin JP, Lehtovirta P. Hereditary aspects of endometrial adenocarcinoma. Int J Cancer 1995; 62: 132–137.
63. Gruber SB, Thompson WD. Rubin GL, Wingo PA, Lee NC, Mandel G et al. A population based study of endometrial cancer and familial risk in younger women. Cancer Epidemiol Biomark Prev 1996; 5: 411–417.
64. Berchuck A, Boyd J. Molecular basis of endometrial cancer. Cancer 1995; 76: 2034–2040.
65. Tritz D, Pieretti M, Turner S, Powell D. Loss of heterozygosity in usual and special variant carcinomas of the endometrium. Hum Pathol 1997; 28: 607–612.
66. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J. Reventos J. Susceptibility to endometrial cancer: influence of allelism at p53, glutathione, S-transferase and cytochrome p450 loci. Br J Cancer 1997; 75: 1385–1388.
67. Bulun SE, Noble LS, Takayama K et al. Endocrine disorders associated with inappropriately high aromatase expression. J Inst Biochem Mol Biol 1997; 61: 133–139.
68. Tseng L, Mozella J, Mann WT, Chumas J. Estrogen synthesis in normal and malignant human endometrium. J Clin Endocrinol Metab 1982; 55: 1029–1031.
69. Randolph JF, Kipersztok S, Ayers JWT, Ansbacker R, Peegal H, Menon KMJ. The effect of insulin on aromatase activity in isolated human endometrial glands and stroma. Am J Obstet Gynecol 1987; 157: 1534–1539.
70. Vadlamuri SV, Glover DD, Turner T, Satkar MA. Region-specific expression of cytochrome p4501 A1 and 1 B1 in human uterine tissue. Cancer Letters 1998; 122: 143–150.
71. Taioli E, Trachman J. Chen X, Toniolo P, Garte SJ. CYP1 A1 restriction fragment length polymorphism is associated with breast cancer in African American women. Cancer Res 1995; 55: 3757–3758.
72. Bailey LR, Roodi N, Verrier CS, Yee CJ, Dupont WD, Parl FF. Breast cancer and CYPIAI, GSTM1 and GSTT1 polymorphisms. Cancer Res 1998; 58: 65–70.
73. Ishibe N, Hankinson SE, Colditz GA et al. Cigarette smoking, cytochrome p450 1A1 polymorphisms and breast cancer risk in the Nurses' Health Study. Cancer Res 1998; 58: 667–671.
74. Guengerich FP. Influence of nutrients and other dietary materials on cytochrome p450 enzymes. Am J Clin Natl 1995; 61 (Suppl): 651–658.
75. Levi F, Franceschi S, Negri E, La Vecchia C. Dietary factors and the risk of endometrial cancer. Cancer 1993; 71: 3575–3581.
76. Barbone F, Austin H, Partridge EE. Diet and endometrial cancer: a case-control study. Am J Epidemiol 1993; 137: 393–403.
77. Hill HA, Austin H. Nutrition and endometrial cancer. Cancer Causes Control 1996; 7: 19–32.
78. Goodman MT, Wilkens LR, Hankin JH, Lyu LC, Wu AH, Kolonel LN. Association of soy and fiber consumption with the risk of endometrial cancer. Am J Epidemiol 1997; 146: 294–306.
79. Zheng W, Kushi LH, Potter JD et al. Dietary intake of energy and animal foods and endometrial cancer incidence: Iowa Womens Health Study. Am J Epidemiol 1995; 142: 388–394.
80. Lissner L, Kroon UB, Bjorntorp B, Blosk S, Wilhelmsen L. Silverstolpe G. Adipose tissue fatty acids and dietary fat sources in relation to endometrial cancer: a retrospective study. Acta Obstet Gynecol Scand 1993; 72: 481–487.
81. Mayer W, Newman B Jr. Selby JV. Usual dietary fat intake and insulin concentrations in healthy women twins. Diab Care 1993; 16: 1459–1469.
82. Feskens EI, Loeber JG, Kromhout D. Diet and physical activity as determinants of hyperinsulinemia: Zutphen elderly study. Am J Epidemiol 1994; 140: 350–360.
83. Bagga D, Capone S, Wang HJ, Heber D, Lill M. Dietary modulation of n-3/n–6 polyunsaturated fatty acid ratios in patients with breast cancer. J Natl Cancer Inst 1997; 89: 1123–1131.
84. Stoll BA, Vatten W, Kvinnsland S. Does early physical maturity influence breast cancer risk Acta Oncol 1994; 33: 171–176.